Skip to main content
. 2017 Jun 15;7(9):2402–2416. doi: 10.7150/thno.17994

Figure 2.

Figure 2

Impact of 89Zr-Df-aTCRmu-F(ab')2 radiation on TCR2.5D6 iRFP TCM (A) Percentage of γH2AX-positive TCR2.5D6 iRFP TCM after 1 h and 48 h of co-incubation with activities of 0 to 1000 µCi (0.0 to 37.0 MBq) 89Zr-Df-aTCRmu-F(ab')2. Mean ± SD of triplicates are shown. (B) Percentage of EMA-positive (dead) TCR2.5D6 iRFP TCM measured 1 h and 48 h after radiotracer exposure at activities of 0 to 1000 µCi (0.0 to 37.0 MBq). Mean ± SD of triplicates are shown. (C) IHC analysis of TCR2.5D6 iRFP TCM infiltrated ML2-B7 tumors after 48 h exposure to 2.2 ± 0.1 MBq i.v. injected 89Zr-Df-aTCRmu-F(ab'). Representative IHC stainings against anti human-CD3, γH2AX and cleaved Caspase-3 of T-cell infiltrated ML2-B7 tumor tissues treated with (lower panel; n=4) and without (upper panel; n=2) radiotracer. Magnification 20X, scale bars equals to 50 µm.